Read More

iDoseTR Approval Sets Stage for Glaukos’ Game-Changing Product, Surpassing Market Expectations, Says Analyst

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension 

GKOS

Read More

FDA Approves Merck’s Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients

The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and

MRK

Read More

Alector Upgraded, Analyst Sees High Reward Potential Ahead of Alzheimer’s Disease Candidate’s Phase 2 Results

Stifel has upgraded Alector Inc (NASDAQ: ALEC), noting that while Alzheimer's is a very high risk, the probability of success for AL002 (TREM2 agonist) is above average, and the stock risk/reward is highly attractive ahead of phase 2 data in expected in Q4 2024.

ALEC